Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progression.
Angermayr M, Roidl A, Bandlow W. Angermayr M, et al. Among authors: roidl a. Mol Microbiol. 2002 Apr;44(2):309-24. doi: 10.1046/j.1365-2958.2002.02881.x. Mol Microbiol. 2002. PMID: 11972772
Rio1p was identified as a protein serine kinase founding a novel subfamily. It is highly conserved from Archaea to man and only distantly related to previously established protein kinase families. ...Cells deprived of Rio1p are enlarged and arrest either in G1 or in …
Rio1p was identified as a protein serine kinase founding a novel subfamily. It is highly conserved from Archaea to man and onl …
V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E. Kubisch R, et al. Among authors: roidl a. Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14. Int J Cancer. 2014. PMID: 24166050
Archazolid is a novel V-ATPase inhibitor. Here, we show that the secretion pattern of archazolid treated cancer cells includes various prometastatic lysosomal proteins like cathepsin A, B, C, D and Z. ...Importantly, in vivo reduced cathepsin B protein as well as …
Archazolid is a novel V-ATPase inhibitor. Here, we show that the secretion pattern of archazolid treated cancer cells includes variou …
Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration.
Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. Mol Cancer. 2014 Jan 27;13:16. doi: 10.1186/1476-4598-13-16. Mol Cancer. 2014. PMID: 24468090 Free PMC article.
Additionally, cells were treated with doxorubicin at a concentration causing a comparable low cytotoxicity, emphasizing the anti-migratory potential of salinomycin. Moreover, single-cell tracking by time-lapse microscopy demonstrated a remarkable effect of sa …
Additionally, cells were treated with doxorubicin at a concentration causing a comparable low cytotoxicity, emphasizing the an …
miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.
Kopp F, Oak PS, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. PLoS One. 2012;7(11):e50469. doi: 10.1371/journal.pone.0050469. Epub 2012 Nov 29. PLoS One. 2012. PMID: 23209748 Free PMC article.
Acquired resistance to classical chemotherapeutics is a major obstacle in cancer treatment. Doxorubicin is frequently used in breast cancer therapy either as single-agent or in combination with other drugs like docetaxel and cyclophosphamide. ...In consequence, we obtained …
Acquired resistance to classical chemotherapeutics is a major obstacle in cancer treatment. Doxorubicin is frequently used in breast …
Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.
Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Oak PS, et al. Among authors: roidl a. Int J Cancer. 2012 Dec 15;131(12):2808-19. doi: 10.1002/ijc.27595. Epub 2012 May 21. Int J Cancer. 2012. PMID: 22511343
A major obstacle in the successful treatment of cancer is the occurrence of chemoresistance. Cancer cells surviving chemotherapy and giving rise to a recurrence of the tumor are termed cancer stem cells and can be identified by elevated levels of certain stem cell m
A major obstacle in the successful treatment of cancer is the occurrence of chemoresistance. Cancer cells surviving chemotherapy and
De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells.
Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A, Ogris M. Kopp F, et al. Among authors: roidl a. Gene Ther. 2013 Nov;20(11):1104-9. doi: 10.1038/gt.2013.37. Epub 2013 Jun 27. Gene Ther. 2013. PMID: 23804075
Moreover, we investigated miR-143-regulated luciferase expression in an NMRI nude/HUH7 xenograft mouse model using a nonviral carrier system for in vivo transfections. ...The use of an miR-143-regulated therapeutic transgene may present a promising approach for canc …
Moreover, we investigated miR-143-regulated luciferase expression in an NMRI nude/HUH7 xenograft mouse model using a nonviral carrier …
A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF‑7 breast cancer cells.
Sommer AK, Hermawan A, Ljepoja B, Fröhlich T, Arnold GJ, Wagner E, Roidl A. Sommer AK, et al. Among authors: roidl a. Int J Mol Med. 2018 Oct;42(4):1987-1997. doi: 10.3892/ijmm.2018.3781. Epub 2018 Jul 18. Int J Mol Med. 2018. PMID: 30066829 Free PMC article.
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, Ho HK. Roidl A, et al. Oncogene. 2010 Mar 11;29(10):1543-52. doi: 10.1038/onc.2009.432. Epub 2009 Nov 30. Oncogene. 2010. PMID: 19946327
Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line MDA-MB453. ...Based on these findings, we propose that FGFR4 may be a driver of tumour growth, particularly when highly expressed or …
Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line …
Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Roidl A, et al. Clin Cancer Res. 2009 Mar 15;15(6):2058-66. doi: 10.1158/1078-0432.CCR-08-0890. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240166
PURPOSE: Establishment of antiapoptotic signaling pathways in tumor cells is a major cause for the failure of chemotherapy against cancer. ...Our findings are exemplary for a novel strategy toward the elucidation of diverse signaling pathways that define antiapoptot …
PURPOSE: Establishment of antiapoptotic signaling pathways in tumor cells is a major cause for the failure of chemotherapy against ca …
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy.
Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, Wagner E. Kubisch R, et al. Among authors: roidl a. Transl Oncol. 2013 Feb;6(1):1-9. doi: 10.1593/tlo.12295. Epub 2013 Feb 1. Transl Oncol. 2013. PMID: 23418611 Free PMC article.
To investigate the complex molecular changes occurring during resistance formation, we performed a comprehensive gene expression analysis of the resistant tumors in vivo. ...Up-regulation of anticoagulatory ANXA3 and PLAT and down-regulation of PLAT inhibitor serpin peptid …
To investigate the complex molecular changes occurring during resistance formation, we performed a comprehensive gene expression anal …
21 results
Jump to page
Feedback